Viatris | VTRS - Gross Profit On Sales



Viatris reported $1.33B in Gross Profit on Sales for its fiscal quarter ending in June of 2025.


Gross Profit On Sales Change Date
Adcock Ingram Holdings ZAR 1.54B 73.26M Dec/2024
Celltrion KRW 442.87B 100.93B Mar/2025
Cspc Pharmaceutical CNY 4.71B 391.66M Mar/2025
Dianthus Therapeutics 193K 970K Jun/2025
Divis Laboratories Ltd 14.54B 1.5B Jun/2025
Kangmei Pharma CNY 223.73M 38.54M Mar/2025
Knight Therapeutics CAD 45.02M 2.32M Sep/2024
Laboratorios Farma EUR 105.28M 177.08M Jun/2025
Malin Corporation EUR 3.8M 2.6M Dec/2020
Medical Developments International AUD 14.72M 1.36M Dec/2024
Organigram Holdings CAD 26.15M 25.1M Jun/2025
Pharma Mar EUR 53.61M 18.15M Jun/2025
Qiagen NV USD 334.29M 25.6M Jun/2025
Sartorius EUR 416.2M 14.8M Jun/2025
Sino Biopharmaceutical CNY 10.5B 2.53B Dec/2024
Tilray USD 61.22M 1.51M Nov/2024
Viatris USD 1.33B 98.1M Jun/2025
Zz Pientze Pharmaceu 296.13M 1.1B Jun/2025